Drug and medical device maker Abbott Laboratories said its first-quarter net income fell 14 percent on restructuring and acquisition costs and other expenses. For the period ended March 31, the company earned $864 million, or 55 cents per share.
A massive database cataloging the human genome's functional elements—including genes, RNA transcripts, and other products—is being made available as an open resource to the scientific community, classrooms, science writers, and the public.
A study of European HIV-positive children shows that 12% of children (around 1 in 8) develop triple-class virological failure by 5 years after starting their antiretroviral drug treatment program.
An Ohio State biophysicist used a supercomputer to search thousands of molecular combinations for the best configuration to block a protein that can cause breast or prostate cancer.
Researchers have found a new way to force cancer cells to self-destruct. Low doses of an anti-cancer drug currently in development sensitizes tumor cells to a second drug, called TRAIL, also being developed as a cancer treatment.
Stanford researchers have developed a new biosensor microchip that could significantly speed up the process of drug development. The microchips, packed with highly sensitive "nanosensors," analyze how proteins bind to one another.
G-Biosciences offers a unique product for the purification of protein from bacterial samples. Our HOOK GST Protein Purification kits allow for the rapid extraction of soluble, GST tagged protein.
TAP Biosystems is introducing three new options for their CompacT SelecT automated cell culture systems that will enable scientists to automate processing of T75 flasks, pipette chilled reagents at low volumes, and optimize oxygen levels.
SciClone Pharmaceuticals, Inc. announced that it has acquired China-based NovaMed Pharmaceuticals Inc. The acquisition brings additional broad sales and marketing to its growing and profitable China focused specialty pharmaceutical business.
DaVita Clinical Research, a provider of clinical research services focused on kidney research as well as a multitude of specialty therapeutic populations, announces the completion of its Phase 1-2a Clean Room to comply with USP 797 high risk regulations.
A new study was begun after neurosurgeons noticed that patients with brain injuries who had been prescribed anti-depressants were doing better in unexpected ways than their counterparts who were not taking such medications.
Medical researchers held out promise that a simple injection is being developed to limit the devastating consequences of heart attacks and strokes. Work has already begun to translate the research into novel clinical therapies.
Nabriva Therapeutics announced the successful results of a Phase 2 clinical trial of BC-3781 in acute bacterial skin and skin structure infections. BC-3781 is the first of a new class of systemically available pleuromutilin antibiotics.
Amarin Corporation plc reported positive top-line results from its ANCHOR trial for the Company’s lead product candidate, AMR101. The Phase 3 trial met its primary and secondary efficacy endpoints for both the 4 gram and 2 gram daily doses.
Eli Lilly and Co. is poised to meet or exceed its goals of cutting annual costs by $1 billion and eliminating 5,500 jobs, Chief Financial Officer Derica Rice said following the drugmaker's first-quarter earnings report.